AbGenomics Corporation intends to use the PER.C6 cell line for its research, development and early clinical studies of monoclonal antibodies.
“The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6 highly imperative,” said Shih-Yao Lin, AbGenomics Corporation’s president.
Under the terms of this agreement, AbGenomics Corporation will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.